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Abstract: This study was designed to assess whether symptoms, functional measures, and
reported disabilities were associated with vitamin B12 (B12) deficiency when defined in
three ways. Participants, aged 60 or more years of age, in 1999–2002 National Health and
Nutrition Examination Surveys (NHANES) were categorized in relation to three previously
used definitions of B12 deficiency: (1) serum B12 < 148 pmol/L; (2) serum B12 < 200 pmol/L
and serum homocysteine > 20 μmol/L; and (3) serum B12 < 258 pmol/L or serum
methylmalonic acid > 0.21 μmol/L. Functional measures of peripheral neuropathy, balance,
cognitive function, gait speed, along with self-reported disability (including activities of
daily living) were examined with standardized instruments by trained NHANES
interviewers and technicians. Individuals identified as B12 deficient by definition 2 were
more likely to manifest peripheral neuropathy OR (odds) (95% confidence intervals),
p value: 9.70 (2.24, 42.07), 0.004 and report greater total disability, 19.61
(6.22, 61.86) 0.0001 after adjustments for age, sex, race, serum creatinine, and ferritin
concentrations, smoking, diabetes, and peripheral artery disease. Smaller, but significantly
increased, odds of peripheral neuropathy and total disability were also observed when
definition 3 was applied. Functional measures and reported disabilities were associated
with B12 deficiency definitions that include B12 biomarkers (homocysteine or
methylmalonic acid). Further study of these definitions is needed to alert clinicians of
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possible subclinical B12 deficiency because functional decline amongst older adults may
be correctable if the individual is B12 replete.
Keywords: vitamin B12 deficiency; methylmalonic acid; homocysteine; peripheral
neuropathy; functional impairment

1. Introduction
Physical disability and cognitive impairment are disorders common among older adults and
represent a major public health concern. Older adults are also at greater risk of vitamin B12 (B12)
deficiency, which is characterized by sensory disturbances and neurological abnormalities, including
cognitive decline, peripheral neuropathy, decreased muscle strength, and functional disability [1,2].
As there appears to be no one indicator that, alone, ascertains whether an individual is either becoming
depleted or deficient in B12 [1], several costly and time-consuming biomarkers are used to assess B12
status. Serum B12 concentrations alone are not necessarily the best indicator for low B12 nutriture
since these may be maintained at the expense of tissue depletion [1,3]. Thus, it is important to confirm
deficiency using additional measurements of biochemical or clinical indicators of B12 nutriture [3].
B12 is a cofactor for methylation reactions involving methylmalonic acid (MMA) and total
homocysteine (homocysteine). Both are elevated when concentrations of B12 are inadequate [1–3].
Some researchers use homocysteine [2,4–7] as an indicator of B12 nutriture, yet homocysteine is not
only an indicator of B12 deficiency; deficiencies of vitamin B6 and folate can result in a buildup in
homocysteine concentrations. The definition of B12 deficiency chosen that incorporates B12 and
homocysteine values has been used to describe the prevalence of “metabolically significant”
deficiency in three different British national cohorts of older adults [2]. Morris et al. [8] used serum
concentrations of B12 or MMA (B12 < 148 pmol/L or MMA > 0.21 μmol/L) to characterize
deficiency, while Johnson and coworkers [9], Pennypacker and colleagues [10], and Stabler and
coworkers [11] have used a more liberal cutoff for B12 (<258 pmol/L) and elevated MMA
(>0.27 μmol/L). Several groups have found that B12 concentrations as high as 258 pmol/L are
accompanied by the presence of abnormal physical signs and symptoms (impaired reflexes, impaired
cognitive function, and missing ankle tendon jerks) consistent with B12 deficiency [12]: however,
many of these findings are based either on case series reports or in cohorts outside the US where food
fortification policies are different. While there is general consensus that individuals with levels
exceeding the common B12 cutoff (<148 pmol/L) may develop neurologic abnormalities and other
signs and symptoms, to the best of our knowledge, there is no national probability-based survey of
these symptoms in the context of definitions of vitamin B12 nutriture that use homocysteine or MMA
with B12 available in the literature. We were particularly interested in applying a definition with
a higher B12 cutoff (<258 pmol/L) with the specific B12 marker MMA to assess whether physical and
sensory impairments might be detected.
The objectives of this study were to describe (1) the prevalence of B12 deficiency in older adults on
the basis of three definitions; first, the traditional definition using serum B12 alone (<148 pmol/L);
second, serum B12 (<200 pmol/L) and homocysteine (>20 μmol/L); and third, serum B12 < 258 pmol/L or
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MMA > 0.21 μmol/L, and (2) the relations of these B12 deficiency definitions to functional measures
available in the National Health and Nutrition Examination Survey (NHANES) for 1999–2000 and
2001–2002. We selected functional measures that historically have been described for B12 deficiency
to determine whether the symptoms and functional measures/disabilities common to this age group and
characteristic of B12 deficiency were observed in participants meeting any of the proposed B12 definitions.
2. Methods
2.1. Study Design
We examined all adults 60 years and older in NHANES 1999–2000 and 2001–2002 (NHANES
1999–2002). We used these data sets as several functional measures and markers of B12 status were
not available in NHANES 2003–2004, 2005–2006, or in more recent surveys (e.g., balance,
lower extremity function, peripheral neuropathy, cognitive function examination, and serum MMA
concentrations). This report is based on the 3105 persons aged 60 years or more who participated in
these surveys and had values for serum vitamin B12, homocysteine, and MMA.
2.2. Biochemical Measurements
In NHANES, the Quantaphase II Folate/Vitamin B12 radioassay kit (Bio-Rad Laboratories,
Hercules, CA, USA) was used to measure serum B12 and folate concentrations. Plasma aliquots were
analyzed for MMA by gas chromatography-mass spectrometry using the reference range for MMA of
0.06 to 0.21 μmol/L for adults with normal creatinine concentrations [13]. Serum creatinine levels
were measured using a Jaffe rate reaction; renal insufficiency was defined at levels >120 μmol/L for
women and >133 μmol/L for men [8]. Plasma homocysteine and mean cell volume are additional
measures of B12 nutriture. Plasma homocysteine concentrations were measured using a fully
automated fluorescence polarization immunoassay (Abbott Diagnostics, Abbott Park, IL, USA). Mean
cell volumes greater than or equal to 99 fL were considered indicative of macrocytosis [8]. Serum
ferritin was acquired to rule out possible confounding affect of inadequate levels. Serum ferritin levels
were measured using the QuantImune Ferritin IRMA kit (Bio-Rad Laboratories, Hercules, CA, USA).
B12 deficiency was defined as follows: (1) B12 < 148 pmol/L (traditional cutoff); (2) B12 < 200 pmol/L
and homocysteine > 20 μmol/L; and (3) B12 < 258 pmol/L or MMA > 0.21 μmol/L.
2.3. Functional Measures
2.3.1. Peripheral Neuropathy Assessment
Two sources in NHANES 1999–2002 were available to assess peripheral neuropathy: (1) a self
administered physical functioning questionnaire and also another one for diabetes in which subjects
self-reported the presence or absence of physical function impairments or specific symptoms of all
adults 40 years and older, and (2) the lower extremity disease examination of insensate areas on both
feet through monofilament testing. For self-reported peripheral neuropathy, the respondent had to
answer affirmatively to two questions about numbness in hands or feet in past 3 months (other than
from falling asleep) and where this numbness was experienced. Another pair of questions address
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whether the respondent experienced a painful sensation or tingling in hands or feet in the past
3 months, and then at which sites this had occurred. For the second, the examination component,
monofilament testing was conducted measuring three points on each foot: the bottom of the foot at the
first metatarsal head, fifth metatarsal head, and halux. An area was insensate if, in two out of three
trials, the subject incorrectly identified when the instrument was placed. Peripheral neuropathy was
defined by the determination of one or more insensate areas [13,14].
2.3.2. Balance
Balance was assessed through a pre-examination questionnaire (inquiries of medications, problems
or procedures that resulted in balance impairment) and balance testing. Balance testing was scored on
a pass/fail basis. A modified Romberg test to assess balance (the vestibular system, vision, and
proprioception) was used with four progressively more difficult test conditions; each condition was
performed twice. According to the NHANES procedure manuals, only adults aged 60–69 years in the
1999–2000 survey were tested, but in 2001–2002, all subjects above 60 years of age were eligible for
testing. For purposes of the current study only, the most difficult test condition (condition 4 testing
vestibular function) was used. This procedure tests one’s ability to stand unassisted without the aid of
vision or proprioception; subjects stand on a foam-padded surface within their eyes closed. As with
previous test conditions, assessment of this outcome was based on the sum of the two possible trials.
2.3.3. Cognitive Functioning
The Digital Symbol Substitution Test (DSST), an executive function measure from the Wechsler
Adult Intelligence Scale, third edition [15], was administered during an in-home interview.
The maximum score for this test is 133 points, which is reflective of the number of correct symbols
drawn within the 120-second time-period. The participant draws symbols to corresponding numbers
provided in the key. The test is regarded as a sensitive one for cognitive impairment and captures the
respondent’s aptitude in response speed, sustained attention, associative learning, visuospatial skills,
and memory. For this study, cognitive impairment was considered to be a score of less than 28, which
was the 25th percentile for the distribution of the study sample.
2.3.4. Gait Speed
Gait speed was measured according to standardized procedures and expressed in seconds to
complete a 20-foot walk [13,14,16,17]. Habitual gait speed was chosen as a measure of walking
function because it may predict subsequent disability [18].
2.3.5. Disability Domains
Participants were also interviewed about functional ability using the physical function questionnaire,
an instrument designed to ascertain the levels of dependence in performing tasks. Possible disability
was classified into four domains as originally described by Nagi [19], using 12 out of the 19 questions
on the instrument; these include: (1) activities of daily living (ADL); (2) instrumental activities of
daily living (IADL); (3) leisure and social activities (LSA); and (4) lower extremity mobility (LEM).
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Examples of the questions for the ADL domain included those about difficulty in eating, getting in and
out of bed or dressing yourself. For the IADL domain, such examples include reported difficulties in
managing money, doing house chores, or preparing meals. For the LSA, these queries include
difficulty in attending social events or going to a movie. For LEM, a respondent might answer
affirmatively to difficulty in walking up ten steps or walking for a quarter of a mile. A participant’s
answer was coded as affirmative if a person reported “much difficulty” or “unable to do the activity”.
Study participants were classified as having one of these disabilities if they reported any of the
symptoms queried. A sum of all four domains was also calculated to determine total disability.
2.3.6. Medical Conditions
Presence of diabetes and coronary heart disease was self-reported in the interview. Another
condition that may affect lower extremity function, peripheral artery disease (PAD), was assessed in
NHANES in the physical function examination. This assessment is one of two components of the
lower extremity function examination in NHANES; the second is the peripheral insensate neuropathy
testing using monofilament testing defined previously (2.3.1). PAD was assessed by the ankle-brachial
index of <0.9 in either leg using an 8.1-MHz Doppler probe (Parks Medical Electronics, Inc., Aloha,
Oregon, USA) [13].
2.3.7. Anthropometrics, Smoking, Alcohol, and Supplement Use
Height and weight were measured using standard protocols and calibrated equipment in the mobile
examination center. Participants reported if they were a current smoker, the average number of
cigarettes smoked per day, and if they drank more than 5 alcoholic drinks a day at any one time.
During the household interview, participants were asked about the ingestion of any vitamin and
mineral supplements in the past 30 days. A participant was classified as a consumer of supplements
containing B12 if he or she reported consuming any supplement with B12 during the past 30 days [13];
no B12 injections were included.
2.3.8. Statistics
The Complex Sample module of SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used for
statistical analyses; the module allows specification of strata and primary sampling units and applies
appropriate sampling weights for study subjects. Data sets from NHANES 1999–2000 and 2001–2002
were combined according to the NHANES analytic guidelines. All outcome variables (biochemical
markers, clinical signs, symptoms, and total scores) were assessed for normality by examination of
histograms, and transformations were performed if necessary. Natural logarithms of serum ferritin and
folate values were used for all subsequent analyses. Significance was assessed with an a priori level
of <0.05.
Descriptive statistics for the analytic sample of 3105 persons were performed using general linear
models for continuous variables with adjustment for the variables included in the basic model: age,
sex, race/ethnicity, smoking status, serum creatinine, serum ferritin, and supplement usage. With
categorical outcomes such as the proportion of females or non-Hispanic whites, cross tabulations are
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presented with no adjustments for possible covariates. Geometric means (±standard error or SE) were
provided based on these analyses.
In our primary analyses, we estimated the prevalence of B12 deficiency when defined by the
previously described definitions using cross-tabulations. These cross-tabulations were repeated for
each age group (60–69, 70–79 and 80–89 years). Independence of those associations was assessed
using the Rao-Scott chi-square test. In effort to better describe the characteristics or attributes of those
adults identified as deficient as compared to those who were not, general linear models were run for
continuous variables, and logistic regression for categorical variables. The basic model includes
adjustment for the previously described variables and diabetes and peripheral artery disease.
Secondary models included B12 supplement use, coronary heart disease, and alcohol use (5 or more
drinks per day). Using logistic regression, odds ratios of B12 deficiency were estimated with adults in
the non-deficient group serving as the reference group.
3. Results
3.1. Demographic Characteristics of Study Population
NHANES 1999–2002 participants in this sample averaged [mean (SE)] 68.9 (0.4) years of age and
were overweight [BMI = 27.1 (0.4)] but had high-normal serum concentrations of ferritin, folate and
MMA, but relatively normal concentrations of B12 and homocysteine (Table 1). Women represented
56.7% of the study participants, and most participants were non-Hispanic white (81.5%). Adults
habitually walked the 20-foot test in an average of 7.7 (0.2) seconds or at a speed of 0.79 meters/second.
Nearly a quarter of the sample reported current smoking. The average number of cigarettes smoked
per day bore a positive relationship with serum cotinine concentrations (β = 0.028, SE = 0.005,
p = 0.0005) (data not shown). Fourteen percent of the population reported having diabetes. Fifteen
percent of the population reported consuming 5 alcoholic drinks per day, which was associated with
increased serum γ-glutamyl transferase concentrations (β = 0.0003, SE = 0.001, p = 0.017) (data not
shown). Based on the cutoff for the DSST, the cognitive function test, 14% of subjects were deemed
cognitively impaired. When comparing the groups by the different deficiency criteria, adults classified
B12 deficient by the 2nd definition were older with higher proportions of peripheral artery disease,
coronary heart disease, diabetes, and had higher creatinine concentrations. Interestingly, the proportion
reporting B12 supplement use was higher in this group and similar to that of the total sample. It is
important to note that this value reflects reported use of a B12 supplement at least once in the past
30 days, not once every day. The proportion of study participants who reported taking B12-containing
supplements differed between race/ethnic groups (data not shown). Nearly 45% of non-Hispanic
whites reported taking B12-containing supplements, but only 23% of non-Hispanic blacks and 26% of
Mexican-Americans consumed these supplements (data not shown). More females reported taking
supplements (44%) than did males (36%). When stratified by gender and race/ethnicity, the proportion
of females in each race/ethnic group that took B12 containing supplements was also higher than that of
men (data not shown).
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Table 1. Demographic characteristics of all National Health and Nutrition Examination
Surveys (NHANES) 1999–2002 participants 60 years and older in the analytic sample and
those classified as vitamin B12 deficient on the basis of three different definitions.

Characteristics

Age (y)
Female (%)
NonHispanic White (%)
Smokers 4 (%)
Body Mass Index, BMI
(kg/m2)
Peripheral artery disease 5
(%)
Coronary heart disease 6 (%)
Diabetes 7 (%)
B12 supplement use 8 (%)
Gait Time 9 (in seconds)
Hematocrit
Macrocytosis 10 (%)
Creatinine (μmol/L)
Ferritin (μg/L)
Folate (nmol/L)
B12 (pmol/L)
Homocysteine (μmol/L)

Total
Sample
(n = 3105)

B12 Alone
(<148 pmol/L)
(n = 95)

Deficiency Definitions 1
B12 (<258 pmol/L)
B12 (<200 pmol/L)
or MMA
and Homocysteine
(>0.21 μmol/L)
(>20 μmol/L) (n = 40)
(n = 1160)
76.6 (1.6)
69.9 (0.5)
78.3 (8.0)
54.7 (1.3)
87.1 (4.9)
82.8 (2.1)
NR
26.2 (2.1)
28.9 (1.3)
27.6 (0.5)

68.9 (0.4) 2
56.7 (0.7) 3
81.5 (2.1)
23.3 (1.3)
27.1 (0.4)

70.9 (1.1)
58.1 (5.3)
81.7 (6.2)
31.4 (8.9)
28.9 (1.0)

6.2 (0.7)

5.5 (3.0)

24.7 (17.0)

8.9 (1.5)

10.3 (0.8)
14.0 (1.4)
41.2 (1.7)
7.7 (0.2)
42.4 (0.2)
4.7 (0.5)
81.1 (1.9)
111.0 (10.0)
42.9 (1.9)
276.6 (12.0)
15.1 (2.4)

11.1 (3.9)
6.7 (3.8)
24.9 (7.2)
7.2 (0.4)
42.6 (0.4)
5.5 (2.1)
85.8 (4.6)
116.0 (17.3)
35.5 (3.0)
149.9 (20.7)
19.9 (4.8)

30.4 (7.5)
19.6 (8.5)
40.3 (8.1)
8.6 (1.0)
39.6 (0.9)
7.0 (4.1)
118.4 (11.4)
95.1 (24.1)
40.0 (8.4)
179.7 (61.9)
37.6 (6.6)

10.3 (0.9)
16.7 (1.2)
29.6 (1.8)
7.9 (0.2)
42.1 (0.2)
5.6 (0.7)
94.2 (3.1)
146.9 (7.8)
39.8 (1.3)
260.5 (8.5)
12.4 (0.5)

1

No statistical comparisons were conducted; 2 Values represent geometric means and standard error (SE)
from general linear models with adjustment for the variables included in the basic model; age, sex,
race/ethnicity, smoking status, serum creatinine, and serum ferritin, and supplement usage; 3 Values represent
sample-weighted mean percentages and SE with no adjustments, measured by cross tabulations; 4 Smoking
status as a current smoker by self-report; NR = no one reported being a current smoker; 5 Peripheral artery
disease defined as ankle-brachial pressure index (ABI) of <0.9; 6 Disease conditions defined by self-report;
7
Disease conditions defined by self-report Individuals reporting borderline diabetes categorized as not
having diabetes; 8 Percent self-reported supplement use of B12 containing supplements in the past 30 days;
9
Gait time in seconds to complete a 20-foot walk; 10 Defined by elevated mean cell volume (MCV) of ≥ 99 fL.

3.2. Prevalence of B12 Deficiency
Exactly 3.2% of the sample was deemed B12 deficient based on definition 1, the traditional cutoff of
<148 pmol B12/L, 1.3% by definition 2 (serum B12 < 200 pmol/L and serum homocysteine > 20 μmol/L),
and 38.3% by definition 3 (serum B12 < 258 pmol/L or serum MMA > 0.21 μmol/L) (Figure 1).
An increase in prevalence rates across age deciles is evident (p < 0.005).
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Figure 1. Crude (unadjusted) prevalence of vitamin B12 deficiency for the total population
and by age decile based on three definitions of deficiency. Bars from left to right:
serum B12 < 148 pmol/L alone (gradient); definition 2, serum B12 < 200 pmol/L and
homocysteine > 20 μmol/L (solid gray) and; the definition 3, serum B12 < 258 pmol/L or
MMA > 0.21 μmol/L (solid black).

3.3. Functional Measures and Reported Disabilities Associated with B12 Deficiency
None of the functional measures was associated with B12 nutriture on the basis of the traditional
cutoff, serum B12 concentrations < 148 pmol/L, except for reported total disability and cognitive
performance as measured by DSST score (Table 2). Adults with serum concentrations less than
148 pmol/L were significantly more likely to be cognitively impaired. A similar relation was noted for
persons classified deficient on the basis of the definition 3, Odds Ratio = 1.58 (1.01, 2.47), p = 0.04.
On the basis of definition 2 (B12/homocysteine), the confidence intervals of most measures were very
large because of the small number of individuals classified as deficient (n = 40). Nevertheless, persons
so classified were at markedly greater odds of peripheral neuropathy upon examination [OR = 9.70
(2.24, 42.07), p = 0.004] and for reporting total disability and, in particular, lower extremity mobility
[OR = 7.58 (1.22, 50.30), p = 0.03]. When definition 3 was used, subjects were more likely to have
peripheral neuropathy [OR = 1.44 (1.03, 2.02), p = 0.03], total disability [OR = 1.60 (1.09, 2.34),
p = 0.02], and disability in leisure and social activity [1.63 (1.06, 2.51), p = 0.03].
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Table 2. Odds of physical impairments and reported disabilities in 3015 persons
60 years and older from NHANES 1999–2000 and 2001–2002 as a function of three
B12 deficiency definitions.
Characteristic

Exam % insensate
% fail
Total
Activities of Daily
Living (ADL)
Instrumental
Activities of Daily
Living (IADL)
Lower extremity
mobility (LEM)
Leisure and social
activities (LSA)

B12 Alone
B12 (<200 pmol/L) and
B12 (<258 pmol/L) or
(<148 pmol/L)
Homocysteine (>20 μmol/L)
MMA (>0.21 μmol/L)
Odds Ratio; (95% Confidence Intervals); p Value
Peripheral Neuropathy 1
0.67; (0.25, 1.78); 0.36 2
9.70; (2.24,42.07); 0.004
1.44; (1.03, 2.02); 0.03
Balance 3
2.08; (0.58, 7.44); 0.25
1.82; (0.20, 16.39); 0.58
0.97; (0.57, 1.64); 0.90
4
Disability
1.80; (1.03, 3.14); 0.04
19.61; (6.22, 61.86); 0.0001
1.60; (1.09, 2.34); 0.02
0.83; (0.12, 5.77); 0.84

2.20; (0.30, 15.88); 0.42

1.57; (0.78, 3.19); 0.98

1.52; (0.46, 5.02); 0.48

2.05; (0.28, 15.20); 0.47

1.36; (0.89, 2.08); 0.15

1.53; (0.65, 3.57); 0.32

7.58; (1.22, 50.30); 0.03

1.44; (0.99, 2.20); 0.06

1.35; (0.04, 4.06); 0.58

4.04; (0.38, 42.61); 0.24

1.63; (1.06, 2.51); 0.03

Cognitive Impairment 5
Digit Symbol
Substitution Test
(DSST)

3.62; (1.45, 9.04); 0.01

0.84; (0.03,23.38); 0.91

1.58; (1.01, 2.47); 0.04

1

Peripheral Neuropathy is defined as having one or more insensate areas. Insensate areas were determined by
monofilament testing completed on three points of each foot; 2 Multivariate adjusted odds ratios; 95%
confidence intervals; p value where the basic model includes age, sex, race/ethnicity, smoking status, serum
creatinine, serum log normal ferritin, diabetes, and peripheral artery disease; 3 Advanced Romberg: Study
participants’ inability to complete or pass the fourth and most difficult balance test of the Romberg Balance
Examination; 4 Disability is defined as impairment in at least one of the following domains: ADL,
IADL, LSA, LEM. Disability within the four domains is defined through the study participant reporting in
a self-report questionnaire the inability to complete a task within the given domain; 5 Cognitive impairment:
≤28 is less than 25th percentile distribution for the DSST for the sample population, where DSST is the
Digit Symbol Substitution Test.

4. Discussion
In the present study of a nationally representative sample of older Americans aged 60 years and
older, we provide information regarding biochemical definitions of B12 deficiency with respect to
signs and symptoms historically associated with B12 deficiency. Several definitions of B12 deficiency
were examined because of the concern that subtle signs might be missed if only the most commonly
used cutoff was employed (serum B12 concentrations < 148 pmol/L). Because of the potential for
irreversible neurological abnormalities associated with B12 deficiency [20,21], it is imperative to
identify the biochemical indicators, signs and symptoms that alert the clinician to possible
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B12 deficiency. Several biochemical definitions have been proposed by researchers to identify
B12 deficiency. These include using higher cutoffs for serum B12 in combination with other metabolic
markers, such as holotranscobalamin, homocysteine, and MMA [5,7,10–12,20,21].
As expected, when the lower, more common cutoff for B12 (<148 pmol/L) was used, prevalence of
deficiency was low (3.2%) compared to 38.3% for definition 3. When the B12/homocysteine definition
was applied, the lowest prevalence was observed, yet this definition was successful at predicting
greater odds of peripheral neuropathy, LEM and total disability. Persons defined by the definition 3
(which reflects a much higher B12 cutoff paired with the specific biomarker, MMA) were also at
greater odds of having peripheral neuropathy and LSA disability.
As mentioned previously, several researchers have found signs and symptoms (cognitive
impairment, missing ankle tendon jerk, sensory abnormalities, and diminished vibratory sense)
in individuals with serum B12 concentrations higher than the more common cutoff of
<148 pmol/L [5,7,10–12,20,21]. These findings provided us with a rationale to explore different
definitions of B12 deficiency wherein physical signs, symptoms, and functional disability may be
observed. Based on the results in the present study, total disability and increased odds of cognitive
impairment were observed when subjects were classified deficient on the basis of serum B12
concentrations (<148 pmol/L) alone. On the basis of a slightly higher B12 (<200 pmol/L) cutoff and
elevated homocysteine concentrations, increased odds of neuropathy, total disability, and lower
extremity immobility were observed, though these estimates should be interpreted with caution
because of the wide confidence intervals noted. Similarly, the addition of MMA to the higher B12
cutoff (<258 pmol/L) or definition 3 was associated with higher likelihood of peripheral neuropathy in
contrast to B12 (<148 pmol/L) definition 1 where such signs were not observed.
Sensory disturbances have also been reported by several researchers in relation to B12
deficiency [5,12,20]. In the present study, we also found increased odds of peripheral neuropathy
among individuals defined as B12 deficient by two of the three definitions. Sensory disturbances
according to Healton et al. [20] were often the first and most common set of symptoms experienced by
B12 deficient individuals (more than 70%). In the InCHIANTI cohort, Leishear and coworkers [5]
observed that older participants whose homocysteine levels became elevated after a six-year follow-up
were at greater odds of being unable to detect monofilament when compared to those with sustained
normal homocysteine levels (OR = 5.4, 1.5–19.0); these individuals also exhibited significantly lower
nerve conduction velocities in comparison to those with normal homocysteine concentrations. Gregg
and coworkers [14] found that the prevalence of peripheral neuropathy rose with increasing age,
though they did not examine these symptoms in the context of B12 nutriture. In agreement with these
researchers, we found that individuals in the highest age decile, 80–89 years, as compared to those in
the lowest, 60–69 years, had more than twice the prevalence of peripheral neuropathy (determined
by examination).
Disability may also be modified by the presence of B12 deficiency. Though several researchers
have explored disability as a function of aging [5,14,22–24], little research is available describing the
domains of disability in relation to B12 status. In the present study, individuals with the MMA/B12
deficiency (definition 3) had 60% increased odds of disability. Matteini et al. [24] evaluated the
association of B-vitamin markers and frailty syndrome as assessed by weight status, grip strength,
endurance, physical activity, and walking speed. These researchers found that B12 insufficiency
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defined by MMA > 0.27 μmol/L was associated with 72% greater odds of frailty (95% CI: 0.92–3.32).
Frail individuals were also significantly more likely to have decreased cognitive performance as
measured by the Mini-Mental State Examination. In the present report, we found that LSA of all the
disability domains was one that was most strongly associated with B12 nutriture when using the
B12/MMA definition. This domain has also been strongly associated with risk of developing
Alzheimer’s disease [23,25]. In a sample of 516 adults in the Chicago Health and Aging cohort, we
found that elevated MMA and low B12 were predictive of faster rates of cognitive decline [26].
Strength and Limitations
The findings of this study (presence of peripheral neuropathy, cognitive impairment, and greater
disability) amongst older adults defined as B12 deficient is important because they are based on
a population-based representative sample of 3105 older adults of diverse race-ethnic backgrounds in
the US. Several of the signs and symptoms measured in this study increase or decrease with the aging
process. However, care was taken to adjust for potential confounding factors to ensure we were
measuring the effect of B12 deficiency and not of other factors. Adjustments were made for age, sex,
race/ethnicity, smoking status, serum creatinine, serum ferritin, diabetes, and peripheral artery disease.
Further adjustments for supplement use, coronary heart disease, and alcohol use resulted in no material
differences in reported associations. Peripheral neuropathy and sensory disturbances are prevalent
among those with diabetes [14], but poor vitamin B12 nutriture may also co-exist [27].
The present research is limited because older NHANES data sets, 1999–2002, were used in order to
include many historically recognized functional indicators of B12 deficiency. Moreover, many of the
historically recognized signs and symptoms were not available in NHANES 1999–2002, such as
sensory measurement on hands (monofilament testing was only available for both feet in NHANES
1999–2001), reflexes, and autonomic assessments. Had other indicators such as ankle tendon reflex or
vibratory sense or nerve conduction velocity testing been included, it might have been possible to
detect more marked effects (as well as a more complete assessment of peripheral neuropathy) when the
definitions of B12 deficiency were applied. As mentioned, impaired balance was one of the historically
recognized signs associated with B12 deficiency. Balance was evaluated only in subjects to the age of
69 in resulting in a smaller sample in NHANES 1999–2000. In the present study we only used
measurements for the most difficult condition (condition 4), which measures vestibular strengths, after
vision and proprioception tests were passed. Perhaps in the selection of the most rigorous condition
we missed detection of subtle proprioceptive impairments. Because of this possible limitation, no
significant relationships were found for balance with any of the B12 deficiency definitions.
Finally, these analyses are based on data from a cross-sectional survey. While these observations
are important on a public health level, our findings cannot be construed to reflect a cause and effect
relationship. Cohort studies can provide a useful means to extend these findings by providing
a temporal picture of B12 nutriture and subsequent presence or absence of symptoms or disability,
such as the recent report by Leshear and coworkers [5].
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5. Conclusions and Implications
In the present study, we have described the prevalence of vitamin B12 deficiency when described
in three ways and report increased odds of several signs and disability with at least two of these
definitions—definitions that include concentrations of functional biomarkers, MMA or homocysteine.
Others have noted that signs and symptoms associated with B12 deficiency in a US case series nearly
two decades ago and in individuals with serum B12 concentrations higher than the commonly used
cutoff of <148 pmol/L [11,20,21]. The present report provides a renewed and more recent rationale for
clinicians to use definitions of B12 deficiency that include homocysteine or MMA. By identifying and
treating a B12 deficiency earlier, it may be possible to prevent some of the functional disabilities
common to individuals as they age but possibly responsive to improved nutrition.
Because of prior evidence of the benefit of early detection, we recommend that cognitive function,
peripheral neuropathy, as well as ankle tendon reflex, vibratory sense, and autonomic function be
assessed in another cohort with a more complete assessment of B12 nutriture. Early detection of
B12 deficiency is critical in the pursuit of improved quality of life and healthcare cost savings. These
findings clearly warrants further confirmation in a setting designed to address these relationships more
thoroughly. The public health consequences in a growing older population could be immense.
Conflicts of Interest
The authors declare no conflict of interest.
References
1.

2.

3.
4.

5.

6.

Institute of Medicine. Vitamin B12. In Dietary Reference Intakes for Thiamin, Riboflavin, Niacin,
Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline; National Academy
Press: Washington, DC, USA, 1998; pp. 306–356.
Clarke, R.; Evans, J.G.; Schneede, J.; Nexo, E.; Bates, C.; Fletcher, A.; Prentice, A.; Johnston, C.;
Ueland, P.M.; Refsum, H.; et al. Vitamin B12 and folate deficiency in later life. Age Ageing 2004,
33, 34–41.
Herbert, V. The 1986 Herman Award Lecture. Nutrition science as a continually unfolding story,
the folate and vitamin B12 paradigm. Am. J. Clin. Nutr. 1987, 46, 387–402.
Bjorkegren, K.; Svardsudd, K. A population-based intervention study on elevated serum levels of
methylmalonic acid and total homocysteine in elderly people, results after 36 months of follow-up.
J. Intern. Med. 2004, 256, 446–452.
Lesihear, K.; Ferucci, L.; Lauretani, F.; Boudreau, R.M.; Studenski, S.A.; Rosano, C.; Abbate, R.;
Gori, A.M.; Corsi, A.M.; DiIorio, A.; et al. Vitamin B12 and homocysteine levels and 6-year
change in peripheral nerve function and neurological signs. J. Gerontol. A Biol. Sci. Med. Sci.
2012, 67, 537–543.
Lewerin, C.; Matousek, M.; Steen, G.; Johansson, B.; Steen, B; Nilsson-Ehle, H. Significant
correlations of plasma homocysteine and serum methylmalonic acid with movement and
cognitive performance in elderly subjects but no improvement from short-term vitamin therapy,
a placebo-controlled randomized study. Am. J. Clin. Nutr. 2005, 81, 1155–1162.

Nutrients 2013, 5
7.

8.

9.

10.

11.
12.

13.

14.

15.

16.

17.

18.

19.
20.

4474

Evatt, M.L.; Terry, P.D.; Ziegler, T.R.; Oakley, G.P. Association between vitamin B12-containing
supplement consumption and prevalence of biochemically defined B12 deficiency in adults in
NHANES III (Third National Health and Nutrition Examination Survey). Public Health Nutr.
2009, 13, 25–31.
Morris, M.S.; Jacques, P.F.; Rosenberg, I.H.; Selhub, J. Folate and vitamin B-12 status in relation
to anemia, macrocytosis and cognitive impairment in older Americans in the age of folic acid
fortification. Am. J. Clin. Nutr. 2007, 85, 193–200.
Johnson, M.A.; Hausman, D.B.; Davey, A.; Poon, L.W.; Allen, R.H.; Stabler, S.P. Vitamin B12
deficiency in African Americans and white octogenarians and centenarians in Georgia. J. Nutr.
Health Aging 2010, 14, 339–345.
Pennypacker, L.C.; Allen, R.H.; Kelly, J.P.; Matthews, L.M.; Grigsby, J.; Kaye, K.; Lindenbaum, J.;
Stabler, S.P. High prevalence of cobalamin deficiency in elderly outpatients. J. Am. Geriatr. Soc.
1992, 40, 1197–1204.
Stabler, S.P.; Allen, R.H.; Savage, D.G.; Lindenbaum, J. Clinical spectrum and diagnosis of
cobalamin deficiency. Blood 1990, 76, 871–881.
Hin, H.; Clarke, R.; Sherliker, P.; Atoyebi, W.; Emmens, K.; Birks, J.; Schneede, J.;
Ueland, P.M.; Nexo, E.; Scott, J.; et al. Clinical relevance of low serum vitamin B12 concentrations
in older people, the Banbury B12 study. Age Ageing 2006, 36, 416–422.
NHANES. Centers for Disease Control and Prevention, National Health and Nutrition Examination
Survey 2001–2002. Available online: http://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?
Component=Examination&CycleBeginYear=2001 (accessed on 18 March 2010).
Gregg, E.W.; Sorlie, P.; Paulose-Ram. R.; Gu, Q.; Eberhardt, M.S.; Wolz, M.; Burt, V.;
Curtin, L.; Engelau, M.; Geiss, L. Prevalence of lower-extremity disease in the US adult
population ≥ 40 years of age with and without diabetes, 1999–2000 National Health and Nutrition
Examination survey. Diabetes Care 2004, 27, 1591–1597.
Wechler, D. Administration and Scoring Guide. In WAIS-III, Wechsler Adult Intelligence Scale,
3rd ed.; The Psychological Corporation, Ed.; Harcourt Brace and Company: San Antonio, TX,
USA, 1997.
Kuo, H.K.; Leveille, S.G.; Yu, Y.-H.; Milberg, W.P. Cognitive function, habitual gait speed, and
late-life disability in the National Health and Nutrition Examination Survey (NHANES) 1999–2002.
Gerontology 2007, 53, 102–110.
Ostchega, Y.; Dillon, C.F.; Lindle, R.; Carroll, M.; Hurley, B.F. Isokinetic leg muscle strength in
older Americans and its relationship to a standardized walk test. Data from the National Health
and Nutrition Examination Survey 1999–2000. J. Am. Geriatr. Soc. 2004, 52, 977–982.
Shinkai, S.; Watanabe, S.; Kumagai, S.; Fujiwara, Y.; Amano, H.; Yoshida, H.; Ishizaki, T.;
Yukama, H.; Suzuki, T.; Shibata, H. Walking speed as a good predictor for the onset of functional
dependence in a Japanese rural community population. Age Ageing 2002, 29, 441–446.
Nagi, S.Z. An epidemiology of disability among adults in the United States. Milbank Mem. Fund
Q. Health Soc. 1976, 54, 439–467.
Healton, H.B.; Savage, D.G.; Brust, J.C.M.; Garrett, T.J.; Lindenbaum, J. Neurologic aspects of
cobalamin deficiency. Medicine 1991, 70, 229–245.

Nutrients 2013, 5

4475

21. Martin, D.C.; Francis, J.; Protetch, J.; Huff, F.J. Time dependency of cognitive recovery with
cobalamin replacement, report of a pilot study. J. Am. Geriatr. Soc.1992, 40, 168–172.
22. Lindenbaum, J.; Rosenberg, I.H.; Wilson, P.W.F.; Stabler, S.P.; Allen, R.H. Prevalence of
cobalamin deficiency in the Framingham elderly population. Am. J. Clin. Nutr. 1994, 60, 2–11.
23. Fabrigoule, C.; Letenneur, L., Dartigues, J.F.; Zarrouk, M.; Commenges, D.; Barberger-Gateau, P.
Social and leisure activities and risk of dementia, a prospective longitudinal study. J. Am. Geriatr.
Soc. 1995, 43, 485–490.
24. Matteini, A.M.; Walston, J.D.; Fallin, M.D.; Bandeed-Roche, K.; Kao, W.H.L.; Semba, R.D.;
Allen, R.H.; Guralnik, J.; Fried, L.P.; Stabler, S.P. Markers of B-vitamin deficiency and frailty in
older women. J. Nutr. Health Aging 2008, 12, 303–308.
25. Scarmeas, N.; Levy, G.; Tang, M.X.; Manly, J.; Stern, Y. Influence of leisure activity on the
incidence of Alzheimer’s disease. Neurology 2001, 57, 2236–2242.
26. Tangney, C.C.; Tang, Y.; Evans, D.A.; Morris, M.C. Biochemical indicators of vitamin B12 and
folate insufficiency and cognitive decline. Neurology 2009, 72, 361–367.
27. Sun, Y.; Lai, M.S.; Lu, C.J. Effectiveness of vitamin B12 on diabetic neuropathy, Systematic
review of clinical controlled trials. Acta Neurol. Taiwan 2008, 14, 48–54.
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article
distributed under the terms and conditions of the Creative Commons Attribution license
(http://creativecommons.org/licenses/by/3.0/).

